A Clinical Study to Evaluate the Long-term Safety of HRS-1893 in Hypertrophic Cardiomyopathy

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 300 participants.

Also called NCT07021963

  • Study
  • In this atlas

Overview

Design
Interventional study; non-randomized; no masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 300 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07021963
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07021963. Non-randomized; no masking; primary purpose treatment. Start 2025-07-04 (actual); primary completion 2027-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Clinical Study to Evaluate the Long-term Safety of HRS-1893 in Hypertrophic Cardiomyopathy
Condition
Hypertrophic Cardiomyopathy
Intervention (Drug)
HRS-1893 Tablet
Lead sponsor
Shandong Suncadia Medicine Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct07021963
Content hash
d45894e79327e2aa6aa2b3d71f03e291b4a59f622187bcc68bd41363ab8ae80d